Current evidence suggests that early and short-term RTX therapy could be an effective treatment option specifically for LGI1, and caspr2 encephalitis, albeit larger studies are needed to confirm this finding (64, 118, 119). This evidence concerns the gene CNTNAP2 and viral encephalitis.